DEBRA SWOVERLAND: Open Payments
NPI 1730500562 · TRAVERSE CITY, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,890 in 160 payments from 28 companies in 2025. Trend: 2023 $2,455 · 2024 $3,458 · 2025 $2,890
Food & beverage: $2,890
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 35 | $469 |
| AstraZeneca Pharmaceuticals LP | 17 | $376 |
| GlaxoSmithKline, LLC. | 16 | $286 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $241 |
| PFIZER INC. | 11 | $228 |
| Lilly USA, LLC | 10 | $169 |
| Otsuka America Pharmaceutical, Inc. | 10 | $136 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $107 |
| Lundbeck LLC | 5 | $99 |
| Astellas Pharma US Inc | 5 | $97 |
Products named: CAPLYTA, REXULTI, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, JARDIANCE, AIRSUPRA, ELIQUIS.
Industry payments across MI — which companies pay providers there.
